Erratum: Treatment of atypical haemolytic uraemic syndrome in the era of eculizumab (CKJ: Clinical Kidney Journal (2012) 5 (4-6) DOI: 10.1093/ckj/sfr177);Treatment of atypical uraemic syndrome in the era of eculizumab

Clinical Kidney Journal

Volumn 5, Issue 1, 2012, Pages 4-6

  Fremeaux Bacchi, Veronique ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

acute kidney disease; atypical HUS; complement; eculizumab; mutations

Indexed keywords

ECULIZUMAB;

HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION;

EID: 84870469243     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfs044     Document Type: Erratum

References (30)

1. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011; 6: 60
2. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; 18: 2392-2400 (Pubitemid 47203855)
3. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844-1859
4. Dragon-Durey MA, Sethi SK, Bagga A et al. Clinical features of anti-factor H autoantibody-Associated hemolytic uremic syndrome. J Am Soc Nephrol 2011; 21: 2180-2187
5. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687
6. de Jorge EG, Macor P, Paixao-Cavalcante D et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 2011; 22: 137-145
7. Le Quintrec M, Roumenina L, Noris M et al. Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. Semin Thromb Hemost 2010; 36: 641-652
8. Zuber J, Le Quintrec M, Sberro-Soussan R et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2010; 7: 23-35
9. Hovinga JA, Vesely SK, Terrell DR et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2009; 115: 1500-1511; quiz 1662
10. Salant DJ. Targeting complement C5 in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2011; 22: 7-9
11. Rother RP, Rollins SA, Mojcik CF et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25: 1256-1264 (Pubitemid 350076509)
12. Al-Akash SI, Almond PS, Savell VH Jr et al. Eculizumab induces long-Term remission in recurrent post-Transplant HUS associated with C3 gene mutation. Pediatr Nephrol 2011; 26: 613-619
13. Chatelet V, Fremeaux-Bacchi V, Lobbedez T et al. Safety and long-Term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009; 9: 2644-2645
14. Davin JC, Gracchi V, Bouts A et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010; 55: 708-711
15. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 544-546
16. Kose O, Zimmerhackl LB, Jungraithmayr T et al. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 2010; 36: 669-672
17. Lapeyraque AL, Fremeaux-Bacchi V, Robitaille P. Efficacy of eculizumab in a patient with factor-H-Associated atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26: 621-624
18. Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1312-1316
19. Nester C, Stewart Z, Myers D et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011; 6: 1488-1494
20. Nurnberger J, Witzke O, Saez AO et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542-544
21. Prescott HC, Wu HM, Cataland SR et al. Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. Am J Hematol 2010; 85: 976-977
22. Tschumi S, Gugger M, Bucher BS et al. Eculizumab in atypical hemolytic uremic syndrome: long-Term clinical course and histological findings. Pediatr Nephrol 2011; 26: 2085-2088
23. Weitz M, Amon O, Bassler D et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26: 1325-1329
24. Zimmerhackl LB, Hofer J, Cortina G et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010; 362: 1746-1748
25. Larrea CF, Cofan F, Oppenheimer F et al. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010; 89: 903-904
26. Legendre C, Babu S, Furman R et al. Safety and Efficacy of Eculizumab in aHUS Patients Resistant to Plasma Therapy: Interim Analysis from a Phase 2 Trial. Abstract presented at the 43rd annual meeting of theAmerican Society of Nephrology, Denver, CO, USA, 16-21 November 2010
27. Muus P, Legendre C, Douglas K et al. Safety and Efficacy of Eculizumab in aHUS Patients on Chronic Plasma Therapy: Interim Analysis of a Phase 2 Trial. Abstract presented at the 43rd annual meeting of the American Society of Nephrology, Denver, CO, USA, 16-21 November 2010
28. Kim JJ, Waller SC, Reid CJ. Eculizumab in atypical haemolytic uraemic syndrome allows cessation of plasma exchange and dialysis. Clin Kidney J 2012; 5: 34-36
29. Garjau M, Azancot M, Ramos R et al. Early treatment with eculizumab may be beneficial in atypical haemolytic uraemic syndrome. Clin Kidney J 2012; 5: 31-33
30. Duran CE, Maduell FM, Campistol JM. Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic uraemic syndrome. Clin Kidney J 2012; 5: 28-30